Completed Access to Information Requests

About this information

Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).

If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.

*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.

Download datasets of the summaries of completed access to information requests.

Current Search

Report Type

Organization

Disposition

Year

Month

Found 385 record(s)

Req # A-2020-00030

Briefing Note prepared for the Minister: MR2020-00149 Gender-Based Violence Products.

Organization: Women and Gender Equality Canada

28 page(s)
March 2021

Req # A-2020-00103

All emails from May 1, 2020 to the present (October 14, 2020) relating to critical race theory (or "CRT"), white privilege, white supremacy, anti-hate, anti-racism, racial sensitivity training, inclusion training, diversity training, Robin DiAngelo, Black Lives Matter (or "BLM"), Antifa. All emails to/from employees, managers, executives and contractors. Please only include electronic documents. For emails related to the specific training sent to employees, it will only be the original email sent to all employees. For any training taken by employees, WAGE will provide the number of employees who completed training related to the above subjects.

Organization: Women and Gender Equality Canada

21 page(s)
March 2021

Req # A-2020-00811

Provide the specific dollar penalties and total claimed by the PMPRB from the use of excessive prices penalty since 2005 and documentation showing what the money was used for.

Organization: Patented Medicine Prices Review Board Canada

0 page(s)
February 2021

Req # A-2020-00813

Copies of documents related to the use of the excessive price penalty against Alexion Pharmaceuticals.

Organization: Patented Medicine Prices Review Board Canada

0 page(s)
February 2021

Req # A-2020-14747

Copies of meeting minutes, presentations and speaking notes associated with rare disease drugs from May 1, 2020 to July 31, 2020.

Organization: Patented Medicine Prices Review Board Canada

654 page(s)
February 2021

Req # A-2020-18436

Provide a detailed disclosure of all third parties consultations over regulation and pricing of new drugs from June 1, 2019 to November 19, 2020, broken down by date, meeting minutes, and summary of meetings.

Organization: Patented Medicine Prices Review Board Canada

474 page(s)
February 2021

Req # A-2020-18440

Copies of all reports, email exchanges, memos, briefing notes, PowerPoints and other similar documents regarding the regulatory process of the United States Food and Drug Administration and the European Union's Medicines Agency compared to the PMPRB guidelines from June 1, 2019 to November 19, 2020.

Organization: Patented Medicine Prices Review Board Canada

409 page(s)
February 2021

Req # A-2021-00810

Copies of all emails to/from and cc'ing Douglas Clark on the excessive prices penalty from January 1, 2019 to January 18, 2021.

Organization: Patented Medicine Prices Review Board Canada

1 page(s)
February 2021

Req # A-2021-00812

The daily calendar of meetings, calls and other taskings for Douglas Clark from June 1, 2019 to January 18, 2021.

Organization: Patented Medicine Prices Review Board Canada

85 page(s)
February 2021

Req # A-2021-00815

Copies of all emails to/from cc'ing Guillaume Coullaird regarding the use of the excessive prices penalty and future use against pharmaceutical companies from January 1, 2019 to January 18, 2021.

Organization: Patented Medicine Prices Review Board Canada

0 page(s)
February 2021
Date modified: